Covalon Tech Ltd (CVALF) 1.0900 $CVALF
The Global Biomaterials Market with Forecasts to 2017 - North America Dominates the Market
M2 - Tue Jul 16, 12:15PM CDT
Research and Markets (http://www.researchandmarkets.com/research/3sm9b2/biomaterials) has announced the addition of the "The Global Biomaterials Market with Forecasts to 2017" report to their offering. The global biomaterial market is estimated to reach $88.4 billion by 2017 from $44.0 billion in 2012, growing at a CAGR of 15%. Increased investments, funding and grants by government bodies worldwide, incessant rise in the number of collaborations, conferences and research-related activities, technological advancements, increasing applications of biomaterials, and growing number of elderly people are the major factors propelling the growth of the biomaterial market globally. Immunological and inflammatory reactions, stringent regulatory systems, issue of fracture fatigue and wear and reimbursement concerns are the major deterrents curbing the biomaterial market. The global biomaterial market witnesses a plethora of growth opportunities. Novel developments of biomaterial for wound healing, plastic surgery,
KYO: 43.25 (+0.34), CRS: 48.37 (-0.93), LNDC: 12.29 (+0.01), ROC: 76.35 (-0.46), SIAL: 134.77 (-0.59), EXAC: 21.08 (+0.08), WMGIZ: 4.38 (-0.04), MTRN: 37.38 (-0.49)
Covalon's ColActive Plus Receives Medicare Billing Codes in Advance of the Symposium on Advanced Wound Care in Denver
ACCESSWIRE-TNW - Wed May 01, 12:59PM CDT
MISSISSAUGA, Ontario - May 1, 2013 - /Newswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon"
(TSXV: COV), an advanced medical technologies company, today announced its Collagen Matrix Dressings, ColActive(R) Plus and ColActive(R) Plus Ag have been assigned Healthcare Common Procedure Coding System (HCPCS) codes for Medicare billing. Covalon's ColActive Plus line of collagen wound dressings are used for treatment of chronic wounds, including diabetic foot ulcers, and have been marketed and sold in the United States and elsewhere since 2005.
COV.VN: 1.300 (-0.060)
Biomaterials Market By Products & Applications - Global Forecasts to 2017
M2 - Thu Apr 04, 8:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cqw856/biomaterials) has announced the addition of the "Biomaterials Market [By Products (Polymers, Metals, Ceramics, Natural Biomaterials) & Applications (Cardiovascular, Orthopedic, Dental, Plastic Surgery, Wound Healing, Tissue Engineering, Ophthalmology, Neurology Disorders)] Global Forecasts to 2017" report to their offering. A biomaterial is a natural or synthetic material suited to replace or treat natural body tissues and organs on interaction with biological systems. It traces its history to more than 2000 years ago, when Romans, Chinese, and Aztecs used gold for dental applications. Biomaterials, which are also biocompatible, have since been adapted, improvised, and technically enabled to improve body functions and replace damaged tissues. They have evolved to include biodegradable materials that are easily dissolved in the body. Advances in technology and the emergence of innovative biomaterial products have enhanced their performa
KYO: 43.25 (+0.34), LNDC: 12.29 (+0.01), SIAL: 134.77 (-0.59), WMGIZ: 4.38 (-0.04), MTRN: 37.38 (-0.49)
Covalon Announces First Quarter Financial Results
CNW Group - Fri Mar 01, 4:00PM CST
Covalon Technologies Ltd. (the "Company" or "Covalon" (TSXV: COV), an advanced medical technologies company, today announced financial results for its first quarter ended December 31, 2012. Revenue for the quarter was $572,006, down 17%, operating expenses were $1,018,752, down 8% and the net loss for the first quarter was $794,481 or $0.01 per share compared to $800,054 or $0.01 per share in the first quarter of the previous year.
COV.VN: 1.300 (-0.060)
Covalon Announces Year End Financial Results and Resignation of Director
CNW Group - Mon Jan 28, 7:00AM CST
Covalon Technologies Ltd. (the "Company" or "Covalon" (TSXV: COV), an advanced medical technologies company, today announced financial results for its year ended September 30, 2012. Revenue for the year was $3,793,451. Revenue was up 47% year over year as a result of the changeover from the old exclusive wound care distribution arrangement to the new path the Company has chosen which is resulting in new agreements.
COV.VN: 1.300 (-0.060)
Covalon Announces Departure of CFO
CNW Group - Wed Jan 09, 6:30AM CST
Covalon Technologies Ltd. (the "Company" or "Covalon" (TSXV: COV), an advanced medical technologies company, today announced the departure of its Chief Financial Officer, Rita Jairam.
COV.VN: 1.300 (-0.060)
The Global Biomaterials Market with Forecasts to 2017 - North America Dominates the Market
M2 - Tue Jul 16, 12:15PM CDT
Research and Markets (http://www.researchandmarkets.com/research/3sm9b2/biomaterials) has announced the addition of the "The Global Biomaterials Market with Forecasts to 2017" report to their offering. The global biomaterial market is estimated to reach $88.4 billion by 2017 from $44.0 billion in 2012, growing at a CAGR of 15%. Increased investments, funding and grants by government bodies worldwide, incessant rise in the number of collaborations, conferences and research-related activities, technological advancements, increasing applications of biomaterials, and growing number of elderly people are the major factors propelling the growth of the biomaterial market globally. Immunological and inflammatory reactions, stringent regulatory systems, issue of fracture fatigue and wear and reimbursement concerns are the major deterrents curbing the biomaterial market. The global biomaterial market witnesses a plethora of growth opportunities. Novel developments of biomaterial for wound healing, plastic surgery,
KYO: 43.25 (+0.34), CRS: 48.37 (-0.93), LNDC: 12.29 (+0.01), ROC: 76.35 (-0.46), SIAL: 134.77 (-0.59), EXAC: 21.08 (+0.08), WMGIZ: 4.38 (-0.04), MTRN: 37.38 (-0.49)
Covalon's ColActive Plus Receives Medicare Billing Codes in Advance of the Symposium on Advanced Wound Care in Denver
ACCESSWIRE-TNW - Wed May 01, 12:59PM CDT
MISSISSAUGA, Ontario - May 1, 2013 - /Newswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon"
(TSXV: COV), an advanced medical technologies company, today announced its Collagen Matrix Dressings, ColActive(R) Plus and ColActive(R) Plus Ag have been assigned Healthcare Common Procedure Coding System (HCPCS) codes for Medicare billing. Covalon's ColActive Plus line of collagen wound dressings are used for treatment of chronic wounds, including diabetic foot ulcers, and have been marketed and sold in the United States and elsewhere since 2005. COV.VN: 1.300 (-0.060)
Biomaterials Market By Products & Applications - Global Forecasts to 2017
M2 - Thu Apr 04, 8:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cqw856/biomaterials) has announced the addition of the "Biomaterials Market [By Products (Polymers, Metals, Ceramics, Natural Biomaterials) & Applications (Cardiovascular, Orthopedic, Dental, Plastic Surgery, Wound Healing, Tissue Engineering, Ophthalmology, Neurology Disorders)] Global Forecasts to 2017" report to their offering. A biomaterial is a natural or synthetic material suited to replace or treat natural body tissues and organs on interaction with biological systems. It traces its history to more than 2000 years ago, when Romans, Chinese, and Aztecs used gold for dental applications. Biomaterials, which are also biocompatible, have since been adapted, improvised, and technically enabled to improve body functions and replace damaged tissues. They have evolved to include biodegradable materials that are easily dissolved in the body. Advances in technology and the emergence of innovative biomaterial products have enhanced their performa
KYO: 43.25 (+0.34), LNDC: 12.29 (+0.01), SIAL: 134.77 (-0.59), WMGIZ: 4.38 (-0.04), MTRN: 37.38 (-0.49)
Covalon Announces First Quarter Financial Results
CNW Group - Fri Mar 01, 4:00PM CST
Covalon Technologies Ltd. (the "Company" or "Covalon"
(TSXV: COV), an advanced medical technologies company, today announced financial results for its first quarter ended December 31, 2012. Revenue for the quarter was $572,006, down 17%, operating expenses were $1,018,752, down 8% and the net loss for the first quarter was $794,481 or $0.01 per share compared to $800,054 or $0.01 per share in the first quarter of the previous year. COV.VN: 1.300 (-0.060)
Covalon Announces Year End Financial Results and Resignation of Director
CNW Group - Mon Jan 28, 7:00AM CST
Covalon Technologies Ltd. (the "Company" or "Covalon"
(TSXV: COV), an advanced medical technologies company, today announced financial results for its year ended September 30, 2012. Revenue for the year was $3,793,451. Revenue was up 47% year over year as a result of the changeover from the old exclusive wound care distribution arrangement to the new path the Company has chosen which is resulting in new agreements. COV.VN: 1.300 (-0.060)
Covalon Announces Departure of CFO
CNW Group - Wed Jan 09, 6:30AM CST
Covalon Technologies Ltd. (the "Company" or "Covalon"
(TSXV: COV), an advanced medical technologies company, today announced the departure of its Chief Financial Officer, Rita Jairam. COV.VN: 1.300 (-0.060)
